We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Genedrive Plc | LSE:GDR | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.375 | -6.12% | 5.75 | 5.50 | 6.00 | 6.25 | 5.75 | 6.25 | 695,108 | 08:11:32 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 55k | -5.15M | -0.0447 | -1.37 | 7.05M |
From Apr 2019 to Apr 2024
TIDMGDR
RNS Number : 0346F
Genedrive PLC
04 March 2020
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that it has granted share options ("Options") to members of its senior management team to acquire a total of 2,169,608 ordinary shares of 1.5p each ("Ordinary Shares") in the Company under the Company's Share Option Scheme.
The Options have been granted with an exercise price equal to the close price on the day before the grant and vest after a period of three years, subject to certain performance criteria being met through achieving revenue targets, achieving cash targets and completing certain strategic projects in the year ending June 2022. The Options are exercisable over the period of 10 years from the date of grant.
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
Hot Features
Premium
1. Details of the person discharging managerial responsibilities
/ person closely associated
a. Name 1. David Budd
2. Matthew Fowler
3. Gino Miele
4. Gordon Powell
5. Colleen Pythian
------------------------------ ----------------------------------------------------------
2. Reason for the notification
------------------------------------------------------------------------------------------
a. Position/status 1. CEO
2. CFO
3. R&D Director
4. Commercial Director
5. Director of Quality & Regulation
------------------------------ ----------------------------------------------------------
a. Initial notification Initial notification
/Amendment
------------------------------ ----------------------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------------------
a. Name genedrive plc
------------------------------ ----------------------------------------------------------
b. LEI 213800ZYODIRZ87Y4K14
------------------------------ ----------------------------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------------------------------
a. Description of Options over ordinary shares of 1.5 pence
the each
Financial instrument,
type
of instrument
Identification GB00B1VKB244
code
------------------------------ ----------------------------------------------------------
b. Nature of the Grant of options pursuant to and in accordance
transaction with the terms of the Company's Share Option
Scheme dated 29 November 2017
------------------------------ ----------------------------------------------------------
c. Price(s) and
volume(s) Volume(s)
Option price(s)
----------
David Budd 9.0p 1,056,982
---------- ----------
Matthew
Fowler 9.0p 672,626
---------- ----------
Gino Miele 9.0p 170,000
---------- ----------
Gordon Powell 9.0p 170,000
---------- ----------
Colleen
Pythian 9.0p 100,000
---------- ----------
------------------------------ ----------------------------------------------------------
d. Aggregated information
* Aggregated volume N/A
* Price
------------------------------ ----------------------------------------------------------
e. Date of the transaction 2020-04-03
------------------------------ ----------------------------------------------------------
f. Place of the Outside a trading venue
transaction
------------------------------ ----------------------------------------------------------
For further details please contact:
genedrive plc +44 (0)161 989 0245
David Budd: CEO / Matthew Fowler:
CFO
Peel Hunt LLP (Nominated Adviser and
Joint Broker) +44 (0)20 7418 8900
James Steel / Oliver Jackson
Stanford Capital Partners Limited
(Joint Broker) +44 (0)20 3815 8880
Patrick Claridge / John Howes
Walbrook PR Ltd (Media Relations & +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Investor Relations)
+44 (0)7980 541 893 / +44
Paul McManus / Anna Dunphy (0)7876 741 001
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHJIMATMTJMBBM
(END) Dow Jones Newswires
March 04, 2020 10:34 ET (15:34 GMT)
1 Year Genedrive Chart |
1 Month Genedrive Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
